nach oben

Clinical Pharmacokinetics

Erschienen in:

01.12.2004 | Original Research Article

Modelling Ciclosporin Double-Peak Absorption Profiles in the Early Post-Transplantation Period

verfasst von: Annick Rousseau, Dr Pierre Marquet

Erschienen in: Clinical Pharmacokinetics | Ausgabe 14/2004

Einloggen, um Zugang zu erhalten

Abstract

Objective

To apply a recent double-peak absorption model to Ciclosporin.

Methods

Pharmacokinetic evaluation was performed in 20 patients who had undergone de novo renal transplantation and were receiving immunosuppressive therapy with corticosteroids, mycophenolate mofetil and Ciclosporin Neoral®. Data were analysed by nonlinear mixed-effects modelling using individual and population approaches.

Results

Six patients presented pharmacokinetic profiles with two peaks, whereas 14 curves apparently had a single, sometimes delayed and wide, peak. A one-compartment model with first-order elimination in association with the double-peak absorption model best fitted the data. This model reliably described the pharmacokinetics of Ciclosporin, whether or not a double peak was present on the concentration-time profiles.

Conclusions

The double-peak absorption model could be useful to optimise Ciclosporin exposure in the early post-transplantation period.

The use of trade names is for product identification purposes only and does not imply endorsement.

Yin OQP, Tomlinson B, Chow AHL, et al. A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine. Clin Pharmacokinet 2003; 42(2): 179–92CrossRefPubMed

Debord J, Risco E, Harel M, et al. Application of a gamma model of absorption to oral cyclosporin. Clin Pharmacokinet 2001; 40(5): 375–82CrossRefPubMed

Leger F, Debord J, Le Meur Y, et al. Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants. Clin Pharmacokinet 2002; 41(1): 71–80CrossRefPubMed

Rousseau A, Monchaud C, Debord J, et al. Bayesian forecasting of oral cyclosporin pharmacokinetics in stable lung transplant recipients with and without cystic fibrosis. Ther Drug Monit 2003; 25(1): 28–35CrossRefPubMed

Beal SL, Sheiner LB. NonMEM users guide (I–VIII). Hanover (MD): GloboMax, 1989-98

Clase CM, Mahalati K, Kiberd BA, et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am J Transplant. 2002; 2(8): 789–95CrossRefPubMed

Levy G, Burra P, Cavallari A, et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation 2002; 73(6): 953–9CrossRefPubMed

Titel: Modelling Ciclosporin Double-Peak Absorption Profiles in the Early Post-Transplantation Period
verfasst von: Annick Rousseau
Dr Pierre Marquet
Publikationsdatum: 01.12.2004
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe 14/2004
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.2165/00003088-200443140-00007

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 14/2004

Avoidance of Bleeding During Surgery in Patients Receiving Anticoagulant and/or Antiplatelet Therapy

Assessment of Levothyroxine Sodium Bioavailability

Effect of Antacid on the Pharmacokinetics of Extended-Release Formulations of Tolterodine and Oxybutynin

Reduction of Saquinavir Exposure by Coadministration of Loperamide

Genetic Predictors of the Clinical Response to Opioid Analgesics

Enterai Drug Absorption in Patients with Short Small Bowel